Allergan

Snapshot
Model updates
Analysis structure

A strong Q2 for Allergan amid key pipeline wins

Allergan records a strong start to 2018 ahead of generic market entries

Allergan reports 12% net revenue growth in Q4 2017

Allergan reports solid quarter as generic pressures loom in 2018
Restasis intellectual property protection
Loss of exclusivity in 2018
Advancement of six key R&D programs
Bibliography

Acquisition trail
Growth Pharma
Acquisitions and R&D spending
Pending loss of exclusivity
Investor pressure and decision to sell women’s health and infectious diseases businesses
Allergan’s SWOT analysis
Allergan’s key events and catalysts
Bibliography

Q1 2018

Allergan’s prescription pharma sales outlook
Allergan’s regional pharma sales outlook
Allergan’s therapy area dynamics
Allergan’s portfolio lifecycle analysis
Allergan’s pipeline analysis
Allergan’s M&A strategy and history
Bibliography

Figure 1: Allergan’s prescription pharmaceutical sales ($m) and growth rate (%), 2014–27
Figure 2: Allergan’s therapy area dynamics, 2017–27
Figure 3: Allergan’s launch/core/expiry portfolio configuration, 2017–27
Figure 4: Allergan’s pipeline overview

Table 1: Allergan’s loss of exclusivity product portfolio
Table 2: Allergan’s sales by therapy area ($m), 2017–27
Table 3: Allergan’s prescription pharmaceutical sales by region ($m), 2017–27
Table 4: Allergan’s sales by therapy area ($m), 2017–27
Table 5: Allergan’s other portfolio sales, by product ($m), 2017–27
Table 6: Allergan’s central nervous system portfolio sales, by product ($m), 2017–27
Table 7: Allergan’s gastroenterology portfolio sales, by product ($m), 2017–27
Table 8: Allergan’s ophthalmology portfolio sales, by product ($m), 2017–27
Table 9: Allergan’s growth drivers and resistors
Table 10: Allergan’s sales by launch, core, and expiry portfolio ($m), 2017–27
Table 11: Allergan’s launch portfolio sales, by product ($m), 2017–27
Table 12: Allergan’s key merger and acquisition deals, 2006–17